Citations 1
Cost-effectiveness of pembrolizumab versus docetaxel for the treatment of previously treated PD-L1 positive advanced NSCLC patients in the United States
Huang, Min , Lou, Yanyan , Pellissier, James M., Burke, Thomas , Liu, Frank Xiaoqing, Velcheti, Vamsidhar , Xu, Ruifeng
Journal of Medical Economics | August 29, 2016 | Volume: 20 | Issue: 2 | Pages: 140-150
